125 related articles for article (PubMed ID: 30668363)
1. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2).
von Hagens C; Walter-Sack I; Goeckenjan M; Storch-Hagenlocher B; Sertel S; Elsässer M; Remppis BA; Munzinger J; Edler L; Efferth T; Schneeweiss A; Strowitzki T
Phytomedicine; 2019 Feb; 54():140-148. PubMed ID: 30668363
[TBL] [Abstract][Full Text] [Related]
2. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).
von Hagens C; Walter-Sack I; Goeckenjan M; Osburg J; Storch-Hagenlocher B; Sertel S; Elsässer M; Remppis BA; Edler L; Munzinger J; Efferth T; Schneeweiss A; Strowitzki T
Breast Cancer Res Treat; 2017 Jul; 164(2):359-369. PubMed ID: 28439738
[TBL] [Abstract][Full Text] [Related]
3. Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.
König M; von Hagens C; Hoth S; Baumann I; Walter-Sack I; Edler L; Sertel S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):413-27. PubMed ID: 26793976
[TBL] [Abstract][Full Text] [Related]
4. Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Berger TG; Dieckmann D; Efferth T; Schultz ES; Funk JO; Baur A; Schuler G
Oncol Rep; 2005 Dec; 14(6):1599-603. PubMed ID: 16273263
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
Pecherstorfer M; Rivkin S; Body JJ; Diel I; Bergström B
Clin Drug Investig; 2006; 26(6):315-22. PubMed ID: 17163265
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Hartley M; Cheema AK; Smaglo B; Hwang JJ; He AR; Weiner LM; Marshall JL; Giaccone G; Liu S; Luecht J; Spiegel JY; Pishvaian MJ
Cancer Chemother Pharmacol; 2018 Mar; 81(3):587-596. PubMed ID: 29392450
[TBL] [Abstract][Full Text] [Related]
8. Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient.
Saeed MEM; Drif AI; Efferth T
Anticancer Res; 2022 Jul; 42(7):3483-3494. PubMed ID: 35790273
[TBL] [Abstract][Full Text] [Related]
9. Assessment of parasite clearance following treatment of severe malaria with intravenous artesunate in Ugandan children enrolled in a randomized controlled clinical trial.
Byakika-Kibwika P; Nyakato P; Lamorde M; Kiragga AN
Malar J; 2018 Oct; 17(1):400. PubMed ID: 30376860
[TBL] [Abstract][Full Text] [Related]
10. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
11. The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells.
Greenshields AL; Fernando W; Hoskin DW
Exp Mol Pathol; 2019 Apr; 107():10-22. PubMed ID: 30660598
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
13. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Generali D; Montemurro F; Bordonaro R; Mafodda A; Romito S; Michelotti A; Piovano P; Ionta MT; Bighin C; Sartori D; Frassoldati A; Cazzaniga ME; Riccardi F; Testore F; Vici P; Barone CA; Schirone A; Piacentini F; Nolè F; Molino A; Latini L; Simoncini EL; Roila F; Cognetti F; Nuzzo F; Foglietta J; Minisini AM; Goffredo F; Portera G; Ascione G; Mariani G
Oncologist; 2017 Jun; 22(6):648-654. PubMed ID: 28432226
[TBL] [Abstract][Full Text] [Related]
14. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
15. Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire.
Assi SB; Aba YT; Yavo JC; Nguessan AF; Tchiekoi NB; San KM; Bissagnéné E; Duparc S; Lameyre V; Tanoh MA
Malar J; 2017 Jan; 16(1):8. PubMed ID: 28049523
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
17. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
[TBL] [Abstract][Full Text] [Related]
18. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.
Sagara I; Beavogui AH; Zongo I; Soulama I; Borghini-Fuhrer I; Fofana B; Camara D; Somé AF; Coulibaly AS; Traore OB; Dara N; Kabore MJ; Thera I; Compaore YD; Sylla MM; Nikiema F; Diallo MS; Dicko A; Gil JP; Borrmann S; Duparc S; Miller RM; Doumbo OK; Shin J; Bjorkman A; Ouedraogo JB; Sirima SB; Djimdé AA
Lancet Infect Dis; 2016 Feb; 16(2):189-98. PubMed ID: 26601738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
